Pfizer Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Pfizer Inc (PFE) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Pfizer Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 63,696M vs 639,352M combined for tracked competitors (9.1% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-5.6% annualized vs trailing 12 months), vs accelerating (+4.4%) for its tracked peer group.
- Growth: Pfizer Inc generated 2.6% revenue growth year over year in Q2 2026, vs 11.2% for its tracked competitors combined.
- Profitability: Its -1.6% net margin compares with 7.3% for the peer group.
- Scale: Pfizer Inc ranks #9 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 3.0% of industry market cap.
- Peer revenue share: Pfizer Inc accounted for 8.3% of combined revenue among its tracked peer group, down from 8.9% a year earlier.
- Peer differentiation: Revenue per employee of $0.85M compares with $0.89M for the peer group (1.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
PFE Sales vs. its Competitors, Q2 2026
Pfizer Inc reported revenue growth of 2.60 % year on year in Q2 2026, below its competitors' combined revenue growth of 11.23 %.
With a net margin of -1.58 %, Pfizer Inc reported lower profitability than its competitors (7.30 %).
Pfizer Inc generated 8.26 % of the combined sales of its peer group, down from 8.90 % a year earlier.
Pfizer Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Pfizer Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Pfizer Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (84) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Pfizer Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs 2.6% for Pfizer Inc. Pfizer Inc's share of combined industry revenue moved from 2.04% to 1.95%, a loss of 0.09 percentage points.
Pfizer Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Pfizer Inc | Yes | No | No | No |
| Competitors combined (203) | ||||
| High-Confidence Competitors (123) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
PFE Stock Performance relative to its Competitors
PFE Stock Performance relative to High-Confidence Competitors
PFE Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Cidara Therapeutics Inc | 282.9% | Outperformed |
| 2 | Ventyx Biosciences Inc | 282.9% | Outperformed |
| 3 | Moderna Inc | 282.9% | Outperformed |
| 4 | Spyre Therapeutics Inc | 282.9% | Outperformed |
| 5 | Revolution Medicines Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Pfizer Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Pfizer Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Pfizer Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Pfizer Inc | 163,675.28 | 63,696.00 |
| Eli Lilly And Company | 1,058,837.89 | 79,665.80 |
| Johnson and Johnson | 663,585.20 | 97,929.00 |
| Abbvie Inc | 471,581.88 | 64,386.00 |
| Merck and Co Inc | 367,264.30 | 66,569.00 |
| Procter and Gamble Co | 361,061.51 | 87,032.00 |
| SUBTOTAL | 5,433,112.23 | 1,012,526.21 |
Sign in to see all competitors of Pfizer Inc.
Sources: Pfizer Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Pfizer Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Pfizer Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Ocugen Inc | Named by the company | 85% |
| Calidi Biotherapeutics Inc | Named by the company | 85% |
| Agios Pharmaceuticals Inc | Named by the company | 85% |
| Alnylam Pharmaceuticals Inc | Named by the company | 85% |
| Sagimet Biosciences inc | Named by the company | 85% |
| Agentix Corp | Named by the company | 85% |
| Nexgel Inc | Named by the company | 85% |
| Macrogenics Inc | Named by the company | 85% |
| Sunshine Biopharma Inc | Named by the company | 85% |
| Amneal Pharmaceuticals Inc | Named by the company | 85% |
| Moderna Inc | Named by the company | 85% |
| Edesa Biotech Inc | Named by the company | 85% |
| Springworks Therapeutics Inc | Named by the company | 85% |
| Ngm Biopharmaceuticals Inc | Named by the company | 85% |
| Urogen Pharma Ltd | Named by the company | 85% |
| Cidara Therapeutics Inc | Named by the company | 85% |
| Oragenics Inc | Named by the company | 85% |
| Palatin Technologies Inc | Named by the company | 85% |
| Skye Bioscience Inc | Named by the company | 85% |
| Morphic Holding inc | Named by the company | 85% |
| Artelo Biosciences Inc | Named by the company | 85% |
| Uniqure N v | Named by the company | 85% |
| Allarity Therapeutics Inc | Named by the company | 85% |
| Sonnet Biotherapeutics Holdings Inc | Named by the company | 85% |
| Fibrobiologics Inc | Named by the company | 85% |
| Biorestorative Therapies Inc | Named by the company | 85% |
| Compass Therapeutics Inc | Named by the company | 85% |
| Mosaic Immunoengineering Inc | Named by the company | 85% |
| Aim Immunotech Inc | Named by the company | 85% |
| Regencell Bioscience Holdings Limited | Named by the company | 85% |
| Shattuck Labs Inc | Named by the company | 85% |
| Bicycle Therapeutics Plc | Named by the company | 85% |
| Greenwich Lifesciences Inc | Named by the company | 85% |
| Can fite Biopharma Ltd | Named by the company | 85% |
| Vanda Pharmaceuticals Inc | Named by the company | 85% |
| Igm Biosciences Inc | Named by the company | 85% |
| Invo Fertility Inc | Named by the company | 85% |
| 22nd Century Group inc | Named by the company | 85% |
| Abvc Biopharma Inc | Named by the company | 85% |
| Protagonist Therapeutics inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Pfizer Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Pfizer Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Pfizer Inc | U.S. Commercial Division 52.92 % |
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.26 % |
| Merck and Co Inc | Pharmaceutical segment 88.88 % |
| Procter and Gamble Co | Fabric & Home Care 34.83 % |
| Amgen Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Pfizer Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Pfizer Inc | 163,675 | 849,280 | 58,267 |
| Eli Lilly And Company | 1,058,838 | 1,593,316 | 534,224 |
| Johnson and Johnson | 663,585 | 695,518 | 149,411 |
| Abbvie Inc | 471,582 | 1,129,579 | 110,807 |
| Merck and Co Inc | 367,264 | 887,587 | 42,267 |
| Procter and Gamble Co | 361,062 | 836,846 | 155,231 |
| PEERS TOTAL | 5,269,437 | 889,338 | 120,304 |
Pfizer Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Pfizer Inc | United States 58.91 % |
| Eli Lilly And Company | United States 61.21 % |
| Johnson and Johnson | United States 57.42 % |
| Merck and Co Inc | EMEA 23.60 % |
| Procter and Gamble Co | Non-US 52.05 % |
| Gilead Sciences Inc | United States 70.78 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Pfizer Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Pfizer Inc's industry classification, broader than the peer set above. Market cap in millions of $.Pfizer Inc ranks #9 of 498 companies by market capitalization in its industry, holding 2.97 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 827, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,062,533 | 19.39 % |
| 2 | Johnson and Johnson | 664,610 | 12.13 % |
| 3 | Beone Medicines Ltd | 545,679 | 9.96 % |
| 4 | Abbvie Inc | 467,633 | 8.54 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 162,678 | 2.97 % |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
Market cap and industry share for the rest of Pfizer Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Pfizer Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 4 | Abbvie Inc | 467,633 | 20.82 % |
| 5 | Merck and Co Inc | 365,684 | 90.79 % |
| 6 | Novartis Ag | 286,994 | 20.10 % |
| 7 | Abbott Laboratories | 176,035 | -24.42 % |
| 8 | Novo Nordisk A | 1,234 | 12.3% |
| 9 | Pfizer Inc | 162,678 | 20.95 % |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 12.3% |
| 11 | Astrazeneca Plc | 1,234 | 12.3% |
| 12 | Bristol myers Squibb Company | 1,234 | 12.3% |
| 13 | Sanofi | 1,234 | 12.3% |
| 14 | Gsk Plc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Pfizer Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Pfizer Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 73.18 % | 64.89 % (avg) | +8.3 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | 16.94 % | -7.21 % (avg) | +24.2 pp |
| Capital Intensity (Capex / Revenue) | 3.79 % | 4.92 % (avg) | -1.1 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Pfizer Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 33.1x | 25.1x | +8.0x |
| EV / EBITDA | 17.8x | 17.3x | +0.5x |
| P/B | 1.6x | 4.5x | -2.9x |
| Return on Equity | 4.91 % | industry aggregate | -12.34 % |
| Return on Invested Capital | - | -2.95 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Pfizer Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 0.90 % | -3.54 % | -7.93 % | 70.62 % | 23.43 % | -41.70 % | 8.77 % | -1.65 % |
| Operating Margin | 26.10 % | 41.08 % | 22.80 % | 23.91 % | 35.78 % | 0.71 % | 19.68 % | 25.34 % |
| Return on Invested Capital | 6.85 % | 11.14 % | 5.29 % | 9.29 % | 14.94 % | 0.15 % | 4.70 % | 6.06 % |
| P/E | 22.0x | 12.7x | 22.0x | 13.9x | 8.9x | 79.0x | 18.6x | 18.6x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Pfizer Inc's BCG Growth-Share Matrix
Relative market share (vs Pfizer Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Pfizer Inc falls in the Dog quadrant: relative market share of 0.15x vs its largest competitor, in an industry growing revenue 8.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Pfizer Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 827 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 3.79 % vs industry average 4.92 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Pfizer Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Pfizer Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Pfizer Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Pfizer Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Pfizer Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 12.3 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-5.6% annualized vs trailing 12 months).
- Low relative market share vs the industry leader (0.15x).
Opportunities
- A meaningful share of tracked competitors (38.50 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Pfizer Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Pfizer Inc | 0.04 | 1.24 | 0.71 |
| Eli Lilly And Company | 0.20 | 1.48 | 1.59 |
| Johnson and Johnson | 0.37 | 1.05 | 0.60 |
| Abbvie Inc | 0.16 | 0.75 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Procter and Gamble Co | 0.25 | 0.71 | 0.71 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Pfizer Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Pfizer Inc | Q2 2026 | +2.6 % | - |
| Eli Lilly And Company | Q2 2026 | +47.7 % | +25.3 % |
| Johnson and Johnson | Q2 2026 | +6.6 % | -0.1 % |
| Abbvie Inc | Q2 2026 | +10.2 % | +284.3 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Procter and Gamble Co | Q2 2026 | +1.5 % | -15.0 % |
| PEERS TOTAL | +8.0 % | -9.0 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Pfizer Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Pfizer Inc | Q2 2026 | +8.3 % | -13.8 % |
| Eli Lilly And Company | Q2 2026 | +33.5 % | +72.8 % |
| Johnson and Johnson | Q2 2026 | +5.5 % | +26.7 % |
| Abbvie Inc | Q2 2026 | -1.3 % | +19.7 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Procter and Gamble Co | Q2 2026 | +2.7 % | +2.7 % |
Pfizer Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Pfizer Inc | 2.12% | 2.53% | 4.91% |
| Eli Lilly And Company | 21.97% | 33.95% | 92.54% |
| Johnson and Johnson | 10.60% | 13.30% | 25.74% |
| Abbvie Inc | 4.68% | 9.11% | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Procter and Gamble Co | 12.72% | 17.81% | 30.05% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Pfizer Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Pfizer Inc | 37.66 | 2.57 |
| Eli Lilly And Company | 39.77 | 13.29 |
| Johnson and Johnson | 31.48 | 6.78 |
| Abbvie Inc | 75.22 | 7.32 |
| Merck and Co Inc | 119.91 | 5.52 |
| Procter and Gamble Co | 22.62 | 4.15 |
| PEERS AVERAGE | 40.94 | 5.37 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.